Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

According to my biotech stock screener, Inotek $ITEK is trading near its 52-week low, has total cash of $137 million and a market cap of only $185 million (these figures could be wrong, please fact check), and has an upcoming catalyst, results for Trabodenoson for glaucoma. The stock has decent volume. Note I have not taken any in-depth look at the science.

Equity offerings - Lantheus Holdings $LNTH is down 10% after hours after announcement of a 3M-share offering. Invitae $NVTA down 8% after hours after a $40M public offering. According to our chatroom, $SGYP too has dilution ahead -

ACADIA Pharmaceuticals $ACAD started ADVANCE, a Phase 2 clinical trial for NUPLAZID (pimavanserin) for adjunctive treatment of patients with negative symptoms of schizophrenia.

Alnylam $ALNY is down 3.9%) and collaboration partner The Medicines Company $MDCO 6.1% after poor midstage data for inclisiran for high cholesterol. There were 54% advserse events resulting from treatment, 9% of which were deemed serious.

Amgen $MGN and development partner Allergan plc $AGN submitted BLA for a biosimilar to Roche's ($RHHBY cancer drug Avastin (bevacizumab). Avastin is one of the major cancer blockbuster drugs whose patent has expired.

RBC Capital Reiterates a Hold Rating on Dynavax
Simos Simeonidis from RBC Capital reiterated a Hold rating on Dynavax $DVAX, with a price target of $4.

Cantor Fitzgerald Reiterates a Buy Rating on Axsome Therapeutics Inc
Chiara Russo from Cantor Fitzgerald reiterated a Buy rating on Axsome Therapeutics Inc $AXSM, with a price target of $13.

Maxim Group Reiterates a Buy Rating on Prima Biomed
Jason McCarthy from Maxim Group reiterated a Buy rating on Prima Biomed $PBMD, with a price target of $5.

Zynerba Pharmaceuticals Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Corey Davis reiterated a Buy rating on Zynerba Pharmaceuticals $ZYNE today.

Kenneth O’keefe’, Director at Jazz Pharmaceuticals (NASDAQ: JAZZ), increased his stake in JAZZ to 17.69%, a total of $1.21 mn, after purchasing for $227.7K yesterday.

Biogen hemophilia spinoff Bioverativ has now Rogerio Vivaldi, M.D. as EVP and chief global therapeutic operations officer and John Greene as EVP and chief financial officer.

Screen Shot 2016-11-16 at 12.41.35 PM

Screen Shot 2016-11-16 at 12.40.48 PM